AI-enabled research workflows ensure both patient awareness of potentially beneficial clinical trials and the highest productivity and performance
At SCOPE 2025, ConcertAI Announces Major Advances in Trial Technologies for Research Sites and Sponsors
Treble
McKenzie Covell
concertai@treblepr.com
At the opening of SCOPE 2025, ConcertAI and Exigent Research announced the availability of ConcertAI technologies for study feasibility, patient-to-trial matching, and AI-powered study automations across all Exigent research sites and as an integral part of all sponsored studies. The partnership ensures that advanced CARAai™ Generative and Agentic AI solutions are available to provide the highest possible performance and lowest burden for the network’s leading community research sites. A few weeks earlier, NeoGenomics and ConcertAI announced the collaborative launch of an AI Software-as-a-Service solution for hematological malignancies, guiding protocol optimization and study design for all major hematological diseases with exceptional biomarker depth and data longitudinality.
At SCOPE, ConcertAI’s Dr. Mike Rossi, PhD, will be leading a session on Rich Clinico-Molecular Real-World Data is Transforming and Accelerating Cancer Clinical Research, discussing how clinical and clinic-genomic co-variates from real-world patient records can tangibly and quantitatively increase confidence in matching of the right patient to the right targeted therapeutic agents as part of clinical trial design. Dr. Rossi presents distinctive evidence through case studies of analyzing human-derived medical records linked with both DNA and RNA sequencing data and Whole Slide Images to de-risk clinical development, all with the objective of accelerating trials for novel therapeutics for patients with the highest unmet medical needs. The session is on Feb. 5 at 9:55 am ET.
About ConcertAI
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203914935/en/
